Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Melanotan I (Afamelanotide) vs SNAP-8
An educational, source-based comparison of Melanotan I (Afamelanotide) and SNAP-8 — how each peptide works, what it's researched for, and what to know before going deeper.
Selective MC1R agonist FDA-approved for erythropoietic protoporphyria.
A selective melanocortin-1 receptor (MC1R) agonist that stimulates eumelanin production in melanocytes. FDA-approved (Scenesse) as an implant for erythropoietic protoporphyria, a rare light-sensitive disorder.
- Erythropoietic protoporphyria (FDA-approved)
- UV-independent tanning (research)
- Photoprotection in photosensitivity disorders
- • FDA-approved for EPP via implant formulation only.
- • Not approved for cosmetic tanning.
- • Monitoring for new/changing moles recommended.
An elongation of the better-known Argireline (Acetyl Hexapeptide-3). Research suggests it modulates SNARE complex formation, reducing the muscle contractions that drive expression lines in topical cosmetic studies.
- Expression-line depth (forehead, crow's feet)
- Skin smoothness endpoints
- • Topical-only application is well tolerated.
- • Effects are modest compared to neurotoxin injectables.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Melanotan I (Afamelanotide) | Afamelanotide for erythropoietic protoporphyria | New England Journal of Medicine | 2015 | Phase 3 trials showed significant pain reduction and sun tolerance. |
| SNAP-8 | Acetyl octapeptide-3 and expression wrinkles | International Journal of Cosmetic Science | 2013 | Reported reduction in wrinkle depth versus placebo in topical trial. |
Side-effect & safety grid
- FDA-approved for EPP via implant formulation only.
- Not approved for cosmetic tanning.
- Monitoring for new/changing moles recommended.
- Topical-only application is well tolerated.
- Effects are modest compared to neurotoxin injectables.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Melanotan I (Afamelanotide) vs SNAP-8 — Key differences
- Class: Melanotan I (Afamelanotide) is classified as Pigmentation · Melanocortin, while SNAP-8 is Skin · Cosmetic.
- Primary research focus: Melanotan I (Afamelanotide) — erythropoietic protoporphyria (fda-approved); SNAP-8 — expression-line depth (forehead, crow's feet).
- Tag: Skin · Pigmentation vs Skin.